Lecture: Hepatorenal Syndrome: Current Concepts

Portal Hypertension IV: Proceedings of the 4th Baveno International Consensus Workshop

Volumn , Issue , 2007, Pages 201-216

  Cárdenas, Andrés ^a   Ginés, Pere ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Cirrhosis; Hepatorenal syndrome; Portal hypertension; Renal perfusion; Renin angiotensin aldosterone system

Indexed keywords

EID: 84986540219     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470988831.ch8     Document Type: Chapter

References (49)

1. Arroyo V, Ginès P, Gerbes A et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology. 1996;23: 164-176.
2. Ginès P, Cárdenas A, Arroyo V, Rodés J. Management of cirrhosis and ascites. N Engl J Med. 2004;350: 1646-1654.
3. Akriviadis E, Botla R, Briggs W et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119: 1637-1648.
4. Moore K. Renal failure in acute liver failure. Eur J Gastroenterol Hepatol. 1999;11: 967-975.
5. Ginès A, Escorsell A, Ginès P et al. Incidence, predictive factors, and prognosis of hepatorenal syndrome in cirrhosis. Gastroenterology. 1993;105:229-236.
6. Epstein M, Berk DP, Hollenberg NK et al. Renal failure in the patient with cirrhosis. The role of active vasoconstriction. Am J Med. 1970;49:175-185.
7. Schrier RW, Arroyo V, BernardiMet al. Peripheral arterial vasodilation hypothesis:a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988;8: 1151-1157.
8. Martin PY, Ginès P, Schrier RW. Role of nitric oxide as mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med. 1998;339: 533-541.
9. Dudley FJ, Esler MD. The sympathetic nervous system in cirrhosis. In: Ginès P, Arroyo V, Rodés J, Schrier RW (eds). Ascites and renal dysfunction in liver disease. 2nd edn, Oxford; Blackwell Publishing, 2005; 54-72.
10. Arroyo V, Clària J, Saló J et al. Antidiuretic hormone and the pathogenesis of water retention in cirrhosis with ascites. Semin Liver Dis. 1994;14: 44-58.
11. Ippolito S, Moore K. Arachidonic acid metabolites and the kidney in cirrhosis. In: Ginès P, Arroyo V, Rodés J, Schrier RW (eds). Ascites and renal dysfunction in liver disease. 2nd edn, Oxford; Blackwell Publishing, 2005; 84-104.
12. Cárdenas A. Hepatorenal syndrome: a dreaded complication of end-stage liver disease. Am J Gastroenterol. 2005;100: 1-8.
13. Follo A, Llovet JM, NavasaMet al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology. 1994;20: 1495-1501.
14. Ruiz-del-Arbol L, Urman J, Fernandez J et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology. 2003;38: 1210-1218.
15. Lee SS. Cardiac dysfunction in spontaneous bacterial peritonitis: a manifestation of cirrhotic cardiomyopathy? Hepatology. 2003;38: 1089-1091.
16. Caregaro L, Menon F, Angeli P et al. Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. Arch Intern Med. 1994;154:201-205.
17. Gines P, Guevara M, Delas Heras D, Arroyo V. Review article: albumin for circulatory support in patients with cirrhosis. Aliment Pharmacol Ther. 2002; 16(suppl. 5):24-31.
18. Cárdenas A, Ginès P, Uriz J et al. Renal failure after upper gastrointestinal bleeding in cirrhosis. Incidence, clinical course, predictive factors and short-term prognosis. Hepatology. 2001;34: 671-676.
19. Ginès P, Guevara M, Arroyo V, Rodes J. Hepatorenal syndrome. Lancet. 2003;362: 1819-1827.
20. Roy L, Legault L, Pomier-Layrargues G. Glomerular filtration rate measurement in cirrhotic patients with renal failure. Clin Nephrol. 1998;50: 342-346.
21. Dudley FJ, Kanel GC, Wood JL et al. Hepatorenal syndrome without sodium retention. Hepatology. 1986;6: 248-259.
22. Cárdenas A, Ginès P. Pathogenesis and treatment of dilutional hyponatremia in cirrhosis. In: Arroyo V, Forns X, Garcia-Pagan JC, Rodes J (eds). Progress in the treatment of liver diseases. Ars Medica, Barcelona, 2003; 31-42.
23. Alessandria C, Venon WD, Marzano A et al. Renal failure in cirrhotic patients:role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol. 2002;14: 1363-1368.
24. Brensing KA, Textor J, Perz J et al. Long-term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut. 2000;47: 288-295.
25. Arroyo V, Terra C, Torre A et al. Hepatorenal syndrome in cirrhosis: clinical features, diagnosis and management. In: Ginès P, Arroyo V, Rodés J, Schrier RW (eds). Ascites and renal dysfunction in liver disease. 2nd edn, Oxford; Blackwell Publishing, 2005; 341-359.
26. Soper CP, Latif AB, Bending MR. Amelioration of hepatorenal syndrome with selective endothelin-A antagonist. Lancet. 1996;347: 1842-1843.
27. Holt S, Goodier D, Marley R et al. Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet. 1999;353: 294-295.
28. Guevara M, Gines P, Fernandez-Esparrach G et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology. 1998;27: 35-41.
29. Gulberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology. 1999;30:870-875.
30. Uriz J, Gines P, Cárdenas A et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol. 2000;33:43-48.
31. Moreau R, Durand F, Poynard T et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology. 2002;122: 923-930.
32. Ortega R, Ginès P, Uriz J et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome. Results of a prospective, non-randomized study. Hepatology. 2002;36: 941-948.
33. Mulkay JP, Louis H, Donckier V et al. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome:a pilot study. Acta Gastroenterol Belg. 2001;64: 15-19.
34. Halimi C, Bonnard P, Bernard B et al. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol. 2002;14: 153-158.
35. Colle I, Durand F, Pessione F et al. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with terlipressin: a retrospective analysis. J Gastroenterol Hepatol. 2002;17:882-888.
36. Solanki P, Chawla A, Garg R et al. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol. 2003;18: 152-156.
37. Angeli P, Volpin R, Gerunda G et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology. 1999;29: 1690-1697.
38. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2004;40: 55-64.
39. Duvoux C, Zanditenas D, Hezode C et al. Effects of noradrenaline and albumin in patients with type 1 hepatorenal syndrome: a pilot study. Hepatology. 2002;36:374-380.
40. Restuccia T, Ortega R, Guevara M et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol. 2004;40: 140-146.
41. Boyer TD. Transjugular intrahepatic portosystemic shunt: current status. Gastroenterology. 2003;124: 1700-1710.
42. Guevara M, Gines P, Bandi JC et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology. 1998;28: 416-422.
43. Ginès P, Uriz J, Calahorra B et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology. 2002;123: 1839-1847.
44. Ochs A, Rössle M, HaagKet al. The transjugular intrahepatic portosystemic stent shunt procedure for refractory ascites. N Engl J Med. 1995;332: 1192-1197.
45. Rossle M, Ochs A, Gulberg V et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med. 2000;8;342:1701-1707.
46. Sanyal AJ, Genning C, Reddy RK et al. Nastra Group. The North American Study of Treatment for Refractory Ascites (NASTRA). Gastroenterology. 2003;124:634-641.
47. Mitzer SR, Stange J, Klammt S et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl. 2000;6: 277-286.
48. Kamath PS, Wiesner RH, Malinchoc M et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33: 464-470.
49. Sort P, Navasa M, Arroyo V et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;5: 403-409.